⌕
Ascendis Pharma · ASND · Nasdaq
Tenet 53 · Mixed
Compare
$271.19−0.20%At closeTenet 53 · Mixed
$271.19−0.54 (−0.20%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Ascendis Pharma (ASND) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (83 new · 144 increased · 92 reduced · 42 closed). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 347 filers, Sep 30, 2026
# 13F FUNDS
347
13F VALUE
$15.7B
69.0M shares
Withheld: the 13F filers report more shares than the company has outstanding, which happens when shared or lent shares are counted twice. The filer count, shares and value are as filed.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 8, 2026Bodenhoff MadsSVP & PAOAcquired · Option exercise3,000$110.00↗
Sep 8, 2026Bodenhoff MadsSVP & PAODisposed · Open-market sale3,000$270.19↗
Sep 8, 2026Bodenhoff MadsSVP & PAODisposed · Option exercise3,000Warrants—↗
Sep 2, 2026HOLTUG LARSdirectorDisposed · Open-market sale236$264.13↗
Aug 14, 2026BIENAIME JEAN JACQUESdirectorAcquired · Open-market buy1,100$245.85↗
Aug 14, 2026BIENAIME JEAN JACQUESdirectorAcquired · Open-market buy900$246.91↗
Jun 2, 2026SMITH SCOTT THOMASEVP & Chief Financial OfficerAcquired · Open-market buy100$219.00↗
May 29, 2026BIENAIME JEAN JACQUESdirectorAcquired · Open-market buy200$223.76↗
May 29, 2026BIENAIME JEAN JACQUESdirectorAcquired · Open-market buy200$222.30↗
May 29, 2026BIENAIME JEAN JACQUESdirectorAcquired · Open-market buy100$223.50↗
May 29, 2026SMITH SCOTT THOMASEVP & Chief Financial OfficerAcquired · Open-market buy250$223.32↗
May 26, 2026BIENAIME JEAN JACQUESdirectorAcquired · Open-market buy200$236.24↗
May 26, 2026BIENAIME JEAN JACQUESdirectorAcquired · Open-market buy200$239.37↗
May 11, 2026JENSEN FLEMMING STEENSee RemarksDisposed · Open-market sale19,460$238.49↗
Apr 14, 2026BIENAIME JEAN JACQUESdirectorDisposed · Disposition to issuer9,160Warrants—↗
Apr 14, 2026BIENAIME JEAN JACQUESdirectorAcquired · Grant / award9,160Warrants—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Ascendis Pharma?

Ascendis Pharma was held by 347 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.